ST Pharm inks $56M deal to produce API for a US biotech
23rd January 2026 Uncategorised 0ST Pharm has struck a $56 million deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for a new oligonucleotide treatment. The Korean CDMO revealed the contract Friday in a regulatory filing.
More: ST Pharm inks M deal to produce API for a US biotech
Source: fierce
